Edition:
United States

Ossur hf (OSSRu.IC)

OSSRu.IC on Iceland Stock Exchange

473.00ISK
19 Jul 2017
Change (% chg)

-- (--)
Prev Close
473.00 kr
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
23,656
52-wk High
500.00 kr
52-wk Low
330.00 kr

Latest Key Developments (Source: Significant Developments)

Ossur Q1 adjusted EBITDA $20 million
Friday, 28 Apr 2017 01:52am EDT 

April 28 (Reuters) - OSSUR HF ::SAID ON THURSDAY Q1 NET SALES $131 MILLION VERSUS $114 MILLION YEAR AGO.Q1 EBITDA ADJUSTED $20 MILLION VERSUS $19 MILLION YEAR AGO.FINANCIAL GUIDANCE FOR THE FULL YEAR OF 2017 IS UNCHANGED.  Full Article

Ossur Q2 adjusted EBITDA up at $30 million
Friday, 22 Jul 2016 01:29am EDT 

Ossur hf : Q2 sales amounted to $139 million compared to $127 million in Q2 2015 . Q2 adjusted EBITDA amounted to $30 million versus $28 million in Q2 2015 . Q2 EBITDA amounted to $25 million or 18 pct of sales . Financial guidance for FY 2016 is unchanged except for capital expenditures .2016 capital expenditures now seen at 5 pct of sales (previously 3-4 pct).  Full Article

Ossur Managing Director of EMEA sells 160,444 Ossur shares at DKK 25.7/SHR
Thursday, 19 May 2016 07:17am EDT 

Ossur hf :Jos van Poorten, Managing Director of EMEA, has on May 19 sold 160,444 Ossur shares at 25.7 Danish crowns ($3.87) per share.  Full Article

Ossur Managing Director of EMEA buys 163,793 Ossur shares
Thursday, 19 May 2016 07:16am EDT 

Ossur Hf :Jos van Poorten, Managing Director of EMEA, bought on May 19 a total of 163,793 Ossur shares at 7.86 Danish crown ($1.18) per share.  Full Article

Ossur says financial guidance for FY 2016 is unchanged
Wednesday, 27 Apr 2016 04:00pm EDT 

Ossur hf:Says financial guidance for FY 2016 is unchanged.Says sales growth in local currencies (LCY) has been added to the guidance following the acquisition of Touch Bionics.Sees sales growth LCY in the range of 7-9 pct.Sees organic sales growth LCY in the range of 3-5 pct.Sees EBITDA margin in the range of 20-21 pct of sales.  Full Article

Ossur acquires Touch Bionics for GBP 27.5 million
Monday, 11 Apr 2016 06:15am EDT 

Ossur hf:Signed agreement to acquire Touch Bionics Limited, a provider of innovative upper limb prostheses and supporting services.Purchase price is 27.5 million British pounds.Touch Bionics has over 120 employees with operations in Scotland, Germany and United States.Acquisition is completed as of April 11.Acquisition does not affect existing share buyback program.Synergies between operations of Ossur and Touch Bionics are expected to be achieved over next 2-3 years.  Full Article

Ossur proposes 2015 dividend of DKK 0.12/shr
Thursday, 18 Feb 2016 03:02am EST 

Ossur hf:Proposes 2015 dividend of DKK 0.12 ($0.0179) per share.  Full Article

Ossur hf announces guidance for FY 2016
Tuesday, 2 Feb 2016 01:00pm EST 

Ossur hf:Sees FY 2016 organic sales growth LCY in the range of 3-5 pct and EBITDA margin in the range of 20-21 pct of sales.Sees FY 2016 capital expenditures in the range of 3-4 pct of sales and effective tax rate of around 26 pct.  Full Article

Ossur hf explores potential for share buy-back block trades
Wednesday, 28 Oct 2015 01:00pm EDT 

Ossur hf:Decided to actively explore potential for share buy-back block trades on NASDAQ Copenhagen and NASDAQ Iceland.Carnegie Investment Bank has been selected as manager of potential block trade on NASDAQ Copenhagen, and Virding Capital Markets has been selected as manager of potential block trade on NASDAQ Iceland.Will also consider commencing a subsequent "Safe Harbour" share buy-back program.Is allowed to purchase own shares of up to 10 pct of its share capital as it stands each time.Purchase price shall not be higher than the price of the last independent trade or the highest current independent bid, whichever is higher, on the regulated market where the transaction is carried out.  Full Article

Ossur hf maintains FY 2015 guidance
Thursday, 22 Oct 2015 08:00pm EDT 

Ossur hf:Financial guidance for FY 2015 is unchanged.FY 2015 guidance includes total sales growth LCY in the range of 4-6 pct, organic sales growth LCY in the range of 3-5 pct and EBITDA margin in the range of 20-21 pct of sales.  Full Article

BRIEF-Ossur Q1 adjusted EBITDA $20 million

* SAID ON THURSDAY Q1 NET SALES $131 MILLION VERSUS $114 MILLION YEAR AGO